BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
July 29, 2021 at 11:49 AM EDT
BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues, partially offset by lower Kuvan product revenues.